全文获取类型
收费全文 | 12986篇 |
免费 | 1186篇 |
国内免费 | 826篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 90篇 |
妇产科学 | 17篇 |
基础医学 | 940篇 |
口腔科学 | 13篇 |
临床医学 | 1532篇 |
内科学 | 6269篇 |
皮肤病学 | 24篇 |
神经病学 | 59篇 |
特种医学 | 475篇 |
外国民族医学 | 1篇 |
外科学 | 960篇 |
综合类 | 2418篇 |
现状与发展 | 5篇 |
预防医学 | 490篇 |
眼科学 | 6篇 |
药学 | 958篇 |
11篇 | |
中国医学 | 517篇 |
肿瘤学 | 212篇 |
出版年
2024年 | 24篇 |
2023年 | 170篇 |
2022年 | 294篇 |
2021年 | 414篇 |
2020年 | 442篇 |
2019年 | 345篇 |
2018年 | 386篇 |
2017年 | 398篇 |
2016年 | 604篇 |
2015年 | 581篇 |
2014年 | 920篇 |
2013年 | 938篇 |
2012年 | 844篇 |
2011年 | 918篇 |
2010年 | 710篇 |
2009年 | 711篇 |
2008年 | 654篇 |
2007年 | 635篇 |
2006年 | 658篇 |
2005年 | 565篇 |
2004年 | 414篇 |
2003年 | 408篇 |
2002年 | 384篇 |
2001年 | 341篇 |
2000年 | 283篇 |
1999年 | 215篇 |
1998年 | 219篇 |
1997年 | 197篇 |
1996年 | 190篇 |
1995年 | 142篇 |
1994年 | 132篇 |
1993年 | 133篇 |
1992年 | 122篇 |
1991年 | 86篇 |
1990年 | 76篇 |
1989年 | 62篇 |
1988年 | 63篇 |
1987年 | 52篇 |
1986年 | 47篇 |
1985年 | 41篇 |
1984年 | 30篇 |
1983年 | 14篇 |
1982年 | 22篇 |
1981年 | 25篇 |
1980年 | 15篇 |
1979年 | 17篇 |
1978年 | 12篇 |
1977年 | 13篇 |
1975年 | 7篇 |
1972年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Diabetes mellitus(DM) negatively affects the development and progression of chronic liver diseases(CLD) of various etiologies. Concurrent DM and CLD are also associated with worse clinical outcomes with respect to mortality, the occurrence of hepatic decompensation, and the development of hepatocellular carcinoma(HCC). Unfortunately, early diagnosis and optimal treatment of DM can be challenging, due to the lack of established clinical guidelines as well as the medical complexity of this patient population. We conducted an exploratory review of relevant literature to provide an up-to-date review for internists and hepatologists caring for this patient population. We reviewed the epidemiological and pathophysiological associations between DM and CLD, the impact of insulin resistance on the progression and manifestations of CLD, the pathogenesis of hepatogenic diabetes, as well as the practical challenges in diagnosis and monitoring of DM in this patient population. We also reviewed the latest clinical evidence on various pharmacological antihyperglycemic therapies with an emphasis on liver disease-related clinical outcomes. Finally, we proposed an algorithm for managing DM in patients with CLD and discussed the clinical and research questions that remain to be addressed. 相似文献
2.
3.
目的探讨扬州地区肝硬化食管静脉曲张初次出血患者诊治特点。方法回顾性分析2010年1月-2013年12月苏北人民医院消化内科收治的80例肝硬化食管静脉曲张初次出血患者病例资料。计数资料用率或构成比表示,率的比较采用χ2检验。结果由乙型肝炎导致肝硬化所引起的食管静脉曲张破裂出血所占比例最大;三腔二囊管临床运用可最大限度地挽救患者生命,为后期治疗提供时间;基础治疗包括止血、输血、抑酸、补液等,后期以硬化剂、套扎、硬化剂+套扎、手术、经颈静脉肝内门体分流术(TIPS)为主,但套扎运用最为广泛;患者出血初期各项指标变化有利于指导临床治疗,对患者预后具有良好的评估作用。结论扬州地区肝硬化引起的食管静脉曲张破裂出血病因呈现复杂交叉性,治疗方法仍需进一步完善,以达到个体化治疗水平;及时正确的救治,对提高临床疗效、降低病死率有重要意义;早期的健康体检,对疾病诊治起关键性的作用。 相似文献
4.
《Annals of hepatology》2020,19(2):190-196
Introduction and objectivesZinc deficiency has been associated with poor prognosis in chronic liver disease. This systematic review and meta-analysis aimed to evaluate the role of zinc supplementation in the management of chronic liver diseases.Materials and methodsWe searched MEDLINE, LILACS, EMBASE, and Cochrane CENTRAL databases from inception to August 2018. We included randomized controlled trials evaluating adult patients with chronic liver disease of any etiology receiving zinc supplementation. Studies with other designs or evaluating chronic conditions other than liver disease were excluded. Two reviewers independently screened and extracted data from eligible studies. Study quality was assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomized studies.ResultsOf 1315 studies screened, 13 were included. Six assessed chronic hepatitis C treatment, with a relative risk of 0.83 indicating no protective effect of zinc supplementation on the improvement of sustained virological response. Three evaluated response to hepatic encephalopathy treatment, with a relative risk of 0.66 indicating a favorable effect of zinc supplementation on clinical improvement of this condition. Of four studies evaluating the management of cirrhosis, two analyzed the effect of zinc supplementation on serum albumin levels, with no statistical difference between zinc and placebo groups.ConclusionsClinical trials assessing zinc supplementation in liver diseases do not show benefits in terms of clinical improvement or disease halting. There are possible benefits of zinc supplementation on hepatic encephalopathy, however, this is based on limited evidence. This research question is still open for evaluation in larger, well-designed, clinical trials. 相似文献
5.
AIM/BACKGROUND: Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown aetiology. Up to 10% of patients with typical features of PBC will have additional features of autoimmune hepatitis (AIH). A subset, however, have no such features but go on to develop a 'sequential' AIH overlap syndrome. Objectives: Describe our experience with eight patients who developed AIH after the diagnosis of PBC was made. METHODS: We reviewed the charts of all PBC patients over a 9-year period (from 1996 to 2005). Only PBC patients with no features of AIH were included. RESULTS: There were 1476 patients with PBC. Of these, eight patients developed features of AIH overlap syndrome based on biochemical and histological parameters. Treatment included prednisone and azathioprine for 24 or more months. The majority of patients remained on ursodeoxycholic acid (UDCA) throughout treatment. Response to therapy was defined by improvement in enzymes, and was rapid for all patients. One patient was able to discontinue treatment with prednisone and azathioprine, while seven have continued on therapy to date. CONCLUSIONS: A 'sequential' overlap syndrome of AIH with PBC can occur. Treatment with prednisone and azathioprine may lead to a rapid improvement in aminotransferase levels. 相似文献
6.
放射性肝纤维化过程的定量研究 总被引:6,自引:0,他引:6
经^60Coγ线照射大鼠肝区,通过光镜、电镜和图像分析仪、宣研究了照后1年肝脏的病理改变。结果表明,30Gy组在照射后1年内逐渐发生了放射性肝纤维化病变。在肝纤维化发生过程中,肝细胞内糖原颗凿含量进行性减少,间质中胶原纤维含量进行性增加,网状纤维于照射1-3个月呈进行性增加。 相似文献
7.
目的:检测激活素(ACT)A对肝星状细胞(HSC)系LI90细胞增殖的影响。方法:采用基因重组人ACT A(0.025-250ng/ml)、转化生长因子-β1(TGF-β1)、镦泡抑素(FS)处理体外培养的人HSC系LI90,采用四唑盐比色法(MTT法)检测其对细胞增殖的影响。结果:ACT A浓度在0.025-250ng/ml范围内,均可刺激LI90细胞增殖,0.025-25ng/ml浓度范围内的ACT A作用轻微,而250ng/ml的ACT A作用明显增强(P<0.01);相反,TGF-β1(2.5ng/ml)对LI90细胞增殖无明显影响;0.315ng/ml FS与浓度为0.25ng/ml的ACT A共同孵育可阻断ACT A促进LI90增殖的活性(P<0.05),而0.315ng/ml FS单独作用对LI 90细胞生长明显影响。结论:ACT可促进HSC增殖,在肝纤维化发病机制中发挥重要作用。 相似文献
8.
J.P. Brouillet B. Hanslick T. Maudelonde M.T. Pivat J. Grenier F. Blanc H. Rochefort 《Clinical biochemistry》1991,24(6):491-496
Using a sandwich enzyme-linked immunoassay, plasma total cathepsin D concentration was assayed in 40 breast cancer patients and 84 patients with various liver diseases and compared to that of 52 normal subjects. There were no significant variations found in breast cancer patients related to tumor size, node invasiveness or metastases. In normal women, cathepsin D levels were slightly but not significantly increased in the luteal phase and in pregnancy. By contrast, plasma cathepsin D concentration was significantly increased in 70-75% of patients with liver disease (cirrhosis, hepatocarcinoma, hepatitis), but not in those with liver steatosis. Cathepsin D was independent of most of the plasma hepatic function tests and was correlated with alpha-fetoprotein in cirrhosis and with alpha-fucosidase in primary hepatocellular carcinoma. We conclude that plasma cathepsin D is not a useful marker in breast cancer. However, since the cellular level of this protease is associated with risk of metastasis in breast cancer, clinical follow-up will be required to test whether high cathepsin D plasma concentration has any prognostic value in liver cirrhosis and primary hepatocarcinoma. 相似文献
9.
肝硬化大鼠肝部分切除术后肝再生的干预研究 总被引:1,自引:0,他引:1
目的 以肝硬化大鼠为动物模型 ,研究药物对肝硬化大鼠肝部分切除术后肝再生的影响。方法 取健康的Wistar雄性大鼠 6 4只 ,以 6 0 ?l4油溶液 0 .3ml/ 10 0 g皮下注射 ,同时饮用 5 %酒精溶液 ,4 5d后制成肝硬化动物模型。模型大鼠随机分为 4组 ,16只 /组。全麻下均行左、中叶肝切除术。术后各组按以下方案处理 :A组 (对照组 )注射生理盐水 1mg/ (kg·d) ,B组为泮托拉唑组 ,注射 0 .2mg/ (kg·d) ,C组为重组人生长激素组 ,注射 0 .5U/ (kg·d) ,D组为两药合用组 ,同时给予泮托拉唑注射 0 .2mg/ (kg·d) ,重组人生长激素注射 0 .5U/ (kg·d) ) ,连续给药 1周。抽取静脉血样 ,取肝脏组织 ,检测肝功能、有丝分裂指数 (MI)、增殖细胞核抗原 (PCNA)、细胞核DNA含量。结果 泮托拉唑组、重组人生长激素组、两药合用组MI、PCNA阳性染色细胞量、细胞核DNA含量均高于对照组 (P <0 .0 5 ) ,两药合用组MI、PCNA阳性染色细胞量、细胞核DNA含量均高于泮托拉唑组、重组人生长激素组 (P <0 .0 5 ) ,但各组间肝功能变化无明显差异。结论 泮托拉唑组及重组人生长激素均对肝硬化大鼠肝部分切除术后肝细胞再生有促进作用 ,两药联合应用肝细胞再生更明显 ,其详细机制须待进一步研究。 相似文献
10.
目的:观察柔肝消瘕饮对肝硬化大鼠肝组织病理形态学和血清、肝组织IL-1β、IL-6含量的影响。方法:采用复合因素造模法复制肝硬化大鼠模型,以复方鳖甲软肝片为对照,观察柔肝消瘢饮对肝硬化大鼠肝组织病理形态学、血清和肝组织IL-1β、IL-6含量的影响。结果:与正常组比较,模型组大鼠出现肝小叶损害,纤维组织增生,假小叶形成,血清IL-1β、IL-6含量和肝组织IL-6含量均明显升高(P〈0.01或P〈0.05);与模型组比较,各治疗组肝组织病理损害减轻,血清IL-1β和肝组织IL-6含量均有明显下降,差异有显著性意义(P〈0.01或P〈0.05);与对照组比较,高剂量组血清IL-6含量明显降低(P〈0.05)。结论:柔肝消瘢饮能显著下调肝硬化大鼠血清IL-1β、IL-6含量和肝组织IL-6含量,具有减轻肝硬化炎症损害,改善肝组织病理形态学作用。 相似文献